ADAM metallopeptidase with thrombospondin type 1 motif 5Genealiases: ADAM-TS 11 · ADAM-TS 5 · ADAM-TS5 · ADAMTS-11 · ADAMTS-5 · ADAMTS11
Q-omics provides the consensus-scored ADAMTS5 profile across patient tissues and cancer cell-line models. ADAMTS5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ADAMTS5 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, ADAMTS5 RNA expression shows 18,070 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and THCA as cancer lineages where ADAMTS5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADAMTS5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADAMTS5 survival associations across molecular data types. ADAMTS5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADAMTS5 RNA expression–survival associations across cancer types. High ADAMTS5 expression shows unfavorable associations in UVM, MESO, KIRP, LIHC and ACC, but favorable associations in UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ADAMTS5 RNA expression.
This table summarizes ADAMTS5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ADAMTS5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADAMTS5 shows lower tumor expression in THCA, BLCA, BRCA and UCEC and higher tumor expression in KIRC and HNSC. The THCA box plot shows higher ADAMTS5 RNA expression in normal versus tumor tissue (log2 FC = −1.414, t-test p < 0.001).
This table shows molecular features associated with ADAMTS5 in patient tissues and cancer cell lines. In patient samples, ADAMTS5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ADAMTS5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SOFT_TISSUE.
